Lipid signatures of West Nile virus infection unveil alterations of sphingolipid metabolism providing novel biomarkers

Abstract

West Nile virus (WNV) is a neurotropic flavivirus transmitted by the bites of infected mosquitoes. Severe forms of West Nile disease (WND) can curse with meningitis, encephalitis or acute flaccid paralysis. A better understanding of the physiopathology associated with disease progression is mandatory to find biomarkers and effective therapies. In this scenario, blood derivatives (plasma and serum) constitute the more commonly used biofluids due to its ease of collection and high value for diagnostic purposes. Therefore, the potential impact of this virus in the circulating lipidome was addressed combining the analysis of samples from experimentally infected mice and naturally WND patients. Our results unveil dynamic alterations in the lipidome that define specific metabolic fingerprints of different infection stages. Concomitant with neuroinvasion in mice, the lipid landscape was dominated by a metabolic reprograming that resulted in significant elevations of circulating sphingolipids (ceramides, dihydroceramides, and dihydrosphingomyelins), phosphatidylethanolamines and triacylglycerols. Remarkably, patients suffering from WND also displayed an elevation of ceramides, dihydroceramides, lactosylceramides, and monoacylglycerols in their sera. The dysregulation of sphingolipid metabolism by WNV may provide new therapeutic opportunities and supports the potential of certain lipids as novel peripheral biomarkers of WND progression.

Glycolytic shift during West Nile virus infection provides new therapeutic opportunities

“…The expression levels of Ccl2 , Cxcl10 , Cxcl11 , and TNF-α were analyzed with Applied Biosystems™ TaqMan™ Array Mouse Immune Response (Applied Biosystems, Waltham, MA, USA), according to manufacturer indications, using GAPDH as endogenous control. The analysis of Hk3 and Slc16a3 expression relative to GAPDH was performed using PrimeTime Std qPCR Assays from Integrated DNA Technologies (Mm.PT.39a.1 for GAPDH , Mm.PT.58.9533034 for Hk3 and Mm.PT.58.8171114 Mm.PT.58.43575827 for Slc16a3 ) as previously described [ 33 ].…”

Mass Spectrometry Detects Sphingolipid Metabolites for Discovery of New Strategy for Cancer Therapy from the Aspect of Programmed Cell Death

“…Sphingolipids, a class of endogenous biologically active molecules with diverse structures, exhibit associations with various diseases due to metabolic disorders within this lipid category [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. The comparative analysis of sphingolipid metabolic networks under different physiological conditions is crucial in identifying key differential metabolites involved in regulating sphingolipid metabolism.…”